MedTrace Logo

Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma

NCT00073983 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2012-03-12

Study results available
· View outcomes & findings →

Summary

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining gemcitabine with docetaxel may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine with docetaxel in treating patients who have recurrent osteosarcoma, recurrent Ewing's sarcoma, or unresectable or locally recurrent chondrosarcoma.

Conditions

  • Sarcoma

Interventions

BIOLOGICAL

filgrastim

filgrastim

BIOLOGICAL

pegfilgrastim

pegfilgrastim

DRUG

docetaxel

docetaxel

DRUG

gemcitabine hydrochloride

gemcitabine hydrochloride

GENETIC

microarray analysis

microarray analysis

OTHER

laboratory biomarker analysis

laboratory biomarker analysis

OTHER

pharmacokinetic study

pharmacokinetic study

Sponsors & Collaborators

  • Sarcoma Alliance for Research through Collaboration

    lead OTHER

Principal Investigators

  • Shreyaskumar R. Patel, MD · Sarcoma Alliance for Research through Collaboration

  • Elizabeth Fox, MD · Sarcoma Alliance for Research through Collaboration

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2010-01-31
Completion
2010-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00073983 on ClinicalTrials.gov